Drug intelligence / Profile preview

ketamine + levobupivacaine

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Paravertebral, Caudal, Intraarticular

Overview

A combination of ketamine and levobupivacaine used for local and regional anesthesia. Ketamine is an NMDA receptor antagonist that produces dissociative anesthesia and analgesia by decreasing the central nervous system's sensitivity to pain. Levobupivacaine is a local anesthetic that blocks sodium channels in peripheral nerves, preventing the transmission of pain signals. When used together, these drugs act synergistically on both central and peripheral components of the pain pathway, providing enhanced and prolonged pain relief with potentially fewer side effects than higher doses of either drug alone.

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)NaV (Voltage-gated sodium channels)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on ketamine + levobupivacaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ketamine + levobupivacaine.

Explore the full profile